Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab - 18/05/20
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
MRONJ is a well-known side effect of various medications, such as antiresorptive drugs, anti-angiogenic agents, immunomodulators and immunosuppressants. MRONJ related to immunotherapy is rarely described, with only one case related to ipilimumab. The interaction between the immune system and osteoclast lineage cells is well known. T cells release factors and cytokines that control osteoclastogenesis, and osteoclasts produce factors with an action on T cells. We attempted to explain how immunotherapy could cause MRONJ through the case report of a young patient with metastatic melanoma who developed maxilla MRONJ after pembrolizumab and epacadostat treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Osteonecrosis, Jaw, Epacadostat, Pembrolizumab, Immunology, Immunotherapy
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?